Ex parte ROBERT R. BARTLETT - Page 10




          Appeal No. 94-2990                                                          
          Application 07/932,577                                                      


          arises why a person having ordinary skill in the art would have             
          considered it desirable to treat those recipients with Bartlett’s           
          composition.  For all this record shows, it would have been more            
          plausible to treat the recipients of xenogeneic transplantation             
          for acute rejection or “accelerated rejection”.  See the Paul               
          text on Fundamental Immunology, relied on by the appellant, page            
          907, section entitled “Acute Rejection”.  Again, the Bartlett               
          reference, considered alone or in conjunction with the remaining            
          references relied on by the examiner, is insufficient to support            
          a conclusion of obviousness of method claims drawn to treating              
          rejection reactions resulting from xenogeneic transplantation.              
          The Bartlett reference, considered alone or in conjunction with             
          the remaining references relied on by the examiner, is                      
          insufficient to support a conclusion of obviousness of claims 16            
          through 21.                                                                 
               As in In re May, 574 F.2d 1082, 1092, 197 USPQ 601, 609                
          (CCPA 1978), “the record reflects both an expected beneficial               
          result . . . and an unexpected beneficial result.”  Consequently,           
          “it is necessary to determine the weight to be accorded each                
          prior to making the ultimate determination on the issue of                  
          obviousness.”  Id.  We have carefully reviewed the Kammerer and             
          Ertel disclosures for motivation to use their compounds to treat            

                                          10                                          





Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  Next 

Last modified: November 3, 2007